» Articles » PMID: 38879615

Molecularly Imprinted Polymer-based Extended-gate Field-effect Transistor Chemosensors for Selective Determination of Antiepileptic Drug

Overview
Journal Mikrochim Acta
Specialties Biotechnology
Chemistry
Date 2024 Jun 15
PMID 38879615
Authors
Affiliations
Soon will be listed here.
Abstract

Ultrathin molecularly imprinted polymer (MIP) films were deposited on the surfaces of ZnO nanorods (ZNRs) and nanosheets (ZNSs) by electropolymerization to afford extended-gate field-effect transistor sensors for detecting phenytoin (PHT) in plasma. Molecular imprinting efficiency was optimized by controlling the contents of functional monomers and the template in the precursor solution. PHT sensing was performed in plasma solutions with various concentrations by monitoring the drain current as a function of drain voltage under an applied gate voltage of 1.5 V. The reliability and reproducibility of the fabricated sensors were evaluated through a solution treatment process for complete PHT removal and PHT adsorption-removal cycling, while selectivity was examined by analyzing responses to chemicals with structures analogous to that of PHT. Compared with the ZNS/extracted-MIP sensor and sensors with non-imprinted polymer (NIP) films, the ZNR/extracted-MIP sensor showed superior responses to PHT-containing plasma due to selective PHT adsorption, achieving an imprinting factor of 4.23, detection limit of 12.9 ng/mL, quantitation limit of 53.0 ng/mL, and selectivity coefficients of 3-4 (against tramadol) and ~ 5 (against diphenhydramine). Therefore, we believe that the MIP-based ZNR sensing platform is promising for the practical detection of PHT and other drugs and evaluation of their proper dosages.

Citing Articles

First Dimension Trap-and-Elute Combined with Second Dimension Reversed-Phase Liquid Chromatography Separation Using a Two-Dimensional-Liquid Chromatography-Tandem Mass Spectrometry System for Sensitive Quantification of Human Insulin and Six Insulin....

Sistik P, Urinovska R, Handlosova K, Handlos P, Andelova K, Jurica J J Sep Sci. 2025; 48(2):e70092.

PMID: 39930590 PMC: 11811267. DOI: 10.1002/jssc.70092.

References
1.
Fisher R, van Emde Boas W, Blume W, Elger C, Genton P, Lee P . Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005; 46(4):470-2. DOI: 10.1111/j.0013-9580.2005.66104.x. View

2.
Hughes D, Bonnett L, Marson A, Garcia-Finana M . Identifying patients who will not reachieve remission after breakthrough seizures. Epilepsia. 2019; 60(4):774-782. PMC: 6487810. DOI: 10.1111/epi.14697. View

3.
Lee-Lane E, Torabi F, Lacey A, Fonferko-Shadrach B, Harris D, Akbari A . Epilepsy, antiepileptic drugs, and the risk of major cardiovascular events. Epilepsia. 2021; 62(7):1604-1616. DOI: 10.1111/epi.16930. View

4.
Algahtani H, Shirah B, AlQahtani A, Al-Malki A . Irreversible Cerebellar Atrophy as a Complication of Short-Term Phenytoin Exposure: Clinical Improvement Following Discontinuation of the Culprit. J Epilepsy Res. 2021; 10(2):96-99. PMC: 7903046. DOI: 10.14581/jer.20016. View

5.
Bagdy G, Kecskemeti V, Riba P, Jakus R . Serotonin and epilepsy. J Neurochem. 2007; 100(4):857-73. DOI: 10.1111/j.1471-4159.2006.04277.x. View